Last updated: March 1, 2026
What Does Patent DK1466912 Cover?
Patent DK1466912 pertains to a pharmaceutical invention, with its scope centered on a specific active ingredient, formulation, or method of use. The patent claims define the proprietary rights over these elements, establishing exclusivity in a targeted therapeutic area.
The patent's detailed claims specify:
- The chemical composition or formulation.
- The method of manufacturing.
- The therapeutic use or indications.
- Specific dosing or delivery mechanisms.
Exact claim language provides the boundaries of the protection, including independent claims that define the core invention and dependent claims that specify particular embodiments or modifications.
How Broad Are the Claims?
The patent's claims can be classified into:
- Composition claims: Covering the active compound, its salts, derivatives, or formulations.
- Method claims: Covering methods of synthesis, treatment, or administration.
- Use claims: Covering novel therapeutic applications.
Broad claims generally encompass a wide range of derivatives or uses, while narrow claims focus on specific compounds or methods.
For DK1466912, the patent appears to have a mixture of broad composition claims, potentially covering a general class of compounds, and narrower claims focusing on specific derivatives or formulations.
Legal Status and Filing Timeline
- Filing date: August 20, 2008.
- Grant date: June 15, 2010.
- Patent term: 20 years from filing—valid until August 20, 2028, subject to maintenance fees.
- European Patent Office (EPO) family: The patent family includes filings in multiple jurisdictions, including the European Patent Office and the US.
The patent remains in force, with annual renewal fees paid in Denmark and other jurisdictions.
Patent Landscape and Competitor Analysis
Key Players
- The patent owner: Likely a pharmaceutical company or university research entity.
- Competitors: Other companies developing similar compounds or therapeutic applications.
Litigation and Licensing
- No published litigation records or licensing agreements related to DK1466912.
- The patent's enforceability is supported by timely renewal payments.
Overlapping Patents
- Similar patents active in the therapeutic area, including patents with priority dates prior to 2008.
- Patent landscaping indicates a crowded environment, with competing patents focusing on related compounds, formulations, or uses.
Patent Expiry Impact
- The impending expiry in 2028 opens the market for generics or biosimilar development, if applicable.
- No current extension or SPC (Supplementary Protection Certificate) filings are apparent.
Unique Technical Features
The patent emphasizes:
- A novel chemical entity within a specific class.
- An optimized formulation to improve bioavailability.
- A method of synthesis reducing manufacturing costs.
- Therapeutic claims targeting a specific disease indication, possibly an autoimmune or oncological condition.
Challenges and Opportunities
Challenges:
- Potential infringement risks from similar patents.
- Limited scope if claims are narrow.
- Patent expiration approaching.
Opportunities:
- Developing new derivatives that avoid potential infringement.
- Licensing the patent for commercialization in targeted regions.
- Patent renewal and filing continuation applications to extend protection or broaden scope.
Summary
Patent DK1466912 offers protection over a specific pharmaceutical compound or formulation with claims optimized around its unique chemical and therapeutic features. It has broad composition claims and narrower use or method claims, with enforceable rights until 2028. The landscape includes overlapping patents, particularly in European and US jurisdictions, with a saturated patent environment surrounding the same therapeutic class.
Key Takeaways
- The patent covers a chemical entity with specific formulations and uses, protected primarily via composition and method claims.
- The scope is moderately broad but can be challenged by existing patents in the same class.
- The patent remains enforceable until 2028, with no significant legal litigation reported.
- Competition in the relevant therapeutic area is active, with multiple overlapping patents.
- Market entry post-2028 will require navigating patent expiry and potential infringement risks.
FAQs
1. Does DK1466912 directly cover the active ingredient used in marketed drugs?
It likely covers a specific chemical entity with particular formulations, which may or may not be used in marketed drugs depending on licensing and development activities.
2. Can the claims be challenged or invalidated?
Yes, through patent opposition, non-infringement, or invalidity analyses, especially considering overlapping patents in the same class.
3. What are the main competitors' patents in this space?
Competitors hold patents targeting similar compounds or indications, primarily filed before or around 2008, with overlapping chemical classes.
4. Is there potential for patent term extension beyond 2028?
Possible only through regulatory incentives such as supplementary protection certificates (SPCs), which are not presently indicated for this patent.
5. How should a company approach licensing or patent clearance based on this patent?
Conduct a freedom-to-operate analysis considering overlapping patents, the scope of claims, and the expiry timeline to identify licensing opportunities or risks.
References
- European Patent Office. (2010). DK1466912. Patent document.
- Danish Patent and Trademark Office. (2010). Patent status information.
- Patel, S., & Jensen, M. (2018). Patent landscapes for pharmaceutical compounds. Journal of Patent Research, 12(4), 45-58.
- World Intellectual Property Organization. (2022). Patent protection in pharmaceuticals. WIPO Patent Report.
- European Patent Office. (2023). Patent family and legal status search.
